| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6365127 | GENZYME | Isolation of a gene encoding human thyrotropin beta subunit |
Nov, 2015
(8 years ago) | |
| US5840566 | GENZYME | Isolation of a gene encoding human thyrotropin beta subunit |
Nov, 2015
(8 years ago) | |
Thyrogen is owned by Genzyme.
Thyrogen contains Thyrotropin Alfa.
Thyrogen has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Thyrogen are:
- US6365127
- US5840566
Thyrogen was authorised for market use on 30 November, 1998.
Thyrogen is available in injectable;injection dosage forms.
Thyrogen can be used as use as adjunct diagnostic for serum thyroglobulin (tg) testing.
The generics of Thyrogen are possible to be released after 24 November, 2015.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 14, 2014 |
Drugs and Companies using THYROTROPIN ALFA ingredient
Market Authorisation Date: 30 November, 1998
Treatment: Use as adjunct diagnostic for serum thyroglobulin (tg) testing
Dosage: INJECTABLE;INJECTION
More Information on Dosage
THYROGEN family patents
